Overweight trials recruiting in Georgia

All Overweight trials nationally

Cities in Georgia

Recruiting trials in Georgia

• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
  NCT07253285 · Phase: Phase 3 · Ages: 8 Years to 18 Years · Sex: All (male and female) · Georgia: Atlanta, Columbus, Decatur, Snellville
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Georgia: Atlanta, Columbus, Lawrenceville, Union City
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Dunwoody, Lawrenceville, Macon
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Dunwoody, Lawrenceville, Stockbridge
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Lawrenceville, Snellville
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Dunwoody, Gainesville, Stockbridge
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
  NCT07215559 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Atlanta, Lawrenceville, Sandy Springs, Stonecrest
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Canton, Decatur, Union City
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Canton, Decatur, Union City
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
  NCT06672939 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Stockbridge
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Georgia: Fayetteville
• AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571005 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Lawrenceville
• AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Lawrenceville
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Georgia: Buford, Columbus, Lawrenceville, Union City
• Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
  NCT07497880 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Decatur
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Lilburn
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · Georgia: Canton, Macon, Savannah
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Georgia: Gainesville, Union City
• Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes
  NCT06735651 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 65 Years · Sex: Female · Georgia: Atlanta
• Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure
  NCT06735599 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 65 Years · Sex: All (male and female) · Georgia: Atlanta